Grifols not currently planning capital increase - source
Reuters
Published Jun 30, 2022 10:56
Updated Jun 30, 2022 12:23
BARCELONA (Reuters) -Spanish pharmaceuticals company Grifols has no current plans for a capital increase, a company executive told investors on Thursday in response to a news report, a source with knowledge of the matter said.
The source said Grifols vice president Nuria Pascual read a statement on behalf of Grifols' chairman, Victor Grifols Roura at an investor day on Thursday, which said: "Regarding the unexpected news published yesterday in Spanish media and replicated by the financial press we want to inform that, for the time being, the board is not analysing any increase in share capital."
Grifols shares surged 6.3% following Pascual's comments, partly rebounding from a 12% decline the previous day.
The shares were hit on Wednesday by reports that the company was negotiating with several funds over a 2-billion-euro ($2.10 billion) capital increase, equivalent to almost 20% of its valuation, to reduce its debt.
Grifols, which specialises in blood plasma-based drugs, held advanced negotiations with funds over a capital hike some time ago but they were inconclusive, another source said.
A spokesperson at Grifols said on Wednesday the company would not comment on market rumours.
In Thursday's presentation to investors, Grifols said revenues were 5% up in the first half of 2022 and its earnings before interest, taxes, depreciation and amortisation (EBITDA) margin was between 20% and 22%.
It also said it expects a strong performance for the second half of the year as it is expanding its plasma collection centres.
Plasma shortages dented Grifols' results in 2020 and 2021 as blood collection collapsed around the world during the pandemic. Its 2021 net profit fell 70% to 183 million euros ($190.70 million)
($1 = 0.9596 euros)
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.